F-genotype mumps virus attenuated strain and construction method therefor and application thereof
AssigneesShanghai King-Cell Biotechnology Co. Ltd., Beijing Cell-Fusion Biotechnology Co., Ltd.
InventorsDayong Tian, Yajing Zhang, Fengcai Zhu, Zhenfang Fu, Lixia Xie, Yuanbao Liu, Juncheng Ruan, Jinliang Wang, Qi An
Life of this patent
Estimating the term…
Abstract
Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus with the accession number of CCTCC NO: V201950. Further provided are a vaccine composition containing the F-genotype mumps virus attenuated strain as an active ingredient and a preparation method thereof.
Claims9
An F genotype mumps virus attenuated strain, which is mumps virus QS-F-SH2 with the accession number of CCTCC NO:
- V201950.
A method for preparing a F genotype mumps virus attenuated strain, which comprises the steps:
- (i) constructing a full-length recombinant plasmid of the F genotype mumps virus that lacks and only lacks the SH gene, comprising the nucleotide sequence represented by SEQ ID NO:
- 3;
- (ii) obtaining three helper plasmids containing the N gene, P gene and L gene in the mumps virus, respectively;
- and
- (iii) co-transfecting host cells with the full-length recombinant plasmid obtained in i) and the three helper plasmids, and after culturing for 3 days, lysing the cells and inoculating into the new cells for culture, and when the cytopathy can be observed, the F genotype mumps virus attenuated strain is obtained.
A method for preparing a vaccine composition, which comprises the steps:
- (i) passaging or culturing the mumps virus QS-F-SH2 with the accession number of CCTCC NO:
- V201950 to obtain an attenuated vaccine strain;
- (ii) mixing the attenuated vaccine strain prepared in step (i) with an immunoacceptable carrier to produce the vaccine composition.
Dependencies are inferred from the claim text.